Drug Index


Mechanism :

Lansoprazole inhibits the gastric H K ATPase (the proton pump) which catalyzes the exchange of H and K. It is effective in the inhibition of both basal acid secretion and stimulated acid secretion.

Indication :

  • Gastric ulcer
  • Duodenal ulcer
  • Pathological hypersecretory conditions including Zollinger-Ellison syndrome
  • Reflux esophagitis including patients with Barrett’s esophagus
  • Eradication of H. pylori.

Contraindications :

In patients with known hypersensitivity to any component of the formulation.

Dosing :

1-3 mg/kg/day orally in two divided doses for 1-2 weeks.
Max: 60 mg/day. Give before meals; do not cut/crush/chew.

Adverse Effect :

Headache, diarrhea, nausea, flatulence, abdominal pain, constipation, and dry mouth.

Interaction :

Cytochrome P450: Lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.
Theophylline: When lansoprazole was administered concomitantly with theophylline, a minor increase (10%) in the clearance of theophylline was seen.
Warfarin: increased International Normalized Ratio (INR) and prothrombin time in patients receiving proton pump inhibitors, including lansoprazole, and warfarin concomitantly. Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.
Lansoprazole has also been shown to have no clinically significant interaction with amoxicillin.
Sucralfate: Absorption of the proton pump inhibitors was delayed, and their bioavailability was reduced. Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.
Lansoprazole causes a profound and long-lasting inhibition of gastric acid secretion; therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin).

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnlikely to be dialysed. Dose as in normal renal function
HDNot dialysed. Dose as in normal renal function
HDF/High fluxUnknown dialysability. Dose as in normal renal function
CAV/VVHDUnknown dialysability, probably not removed. Dose as in normal renal function

Hepatic Dose :

Specific recommendations for dose adjustments in hepatic impairment are not available. Consider dosage reduction in patients with severe hepatic disease.
03/20/2024 20:18:53 Lansoprazole
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0